Your browser is no longer supported. Please, upgrade your browser.
Settings
CNAT Conatus Pharmaceuticals Inc. daily Stock Chart
CNAT [NASD]
Conatus Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own0.40% Shs Outstand26.07M Perf Week4.14%
Market Cap196.55M Forward P/E28.35 EPS next Y0.27 Insider Trans0.00% Shs Float25.30M Perf Month71.36%
Income-29.70M PEG- EPS next Q-0.25 Inst Own29.20% Short Float5.60% Perf Quarter63.56%
Sales0.80M P/S245.68 EPS this Y-1.20% Inst Trans1.20% Short Ratio2.38 Perf Half Y292.71%
Book/sh0.84 P/B8.98 EPS next Y132.50% ROA-64.80% Target Price13.43 Perf Year158.22%
Cash/sh2.95 P/C2.55 EPS next 5Y38.00% ROE-108.90% 52W Range1.45 - 8.05 Perf YTD43.07%
Dividend- P/FCF7.31 EPS past 5Y35.60% ROI-130.80% 52W High-4.84% Beta1.28
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low428.28% ATR0.54
Employees25 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)74.23 Volatility7.95% 9.82%
OptionableYes Debt/Eq0.05 EPS Q/Q-14.90% Profit Margin- Rel Volume0.83 Prev Close7.54
ShortableYes LT Debt/Eq0.00 EarningsMar 15 AMC Payout- Avg Volume596.07K Price7.66
Recom1.70 SMA2023.56% SMA5042.74% SMA200132.60% Volume396,563 Change1.59%
Mar-16-17Reiterated Stifel Buy $7 → $9
Dec-20-16Reiterated Stifel Buy $5 → $7
Dec-20-16Reiterated H.C. Wainwright Buy $9 → $18
Nov-09-16Reiterated Stifel Buy $6 → $5
Jul-01-16Resumed ROTH Capital Buy
Nov-05-15Reiterated Stifel Buy $11 → $9
Sep-22-15Initiated H.C. Wainwright Buy $15
Apr-28-15Initiated Brean Capital Buy $13
Mar-17-15Resumed ROTH Capital Buy $15
Mar-12-15Reiterated Stifel Buy $13 → $11
Jan-09-15Reiterated ROTH Capital Buy $19 → $12
Oct-21-14Initiated MLV & Co Buy $16
Aug-14-14Reiterated Stifel Buy $14 → $13
Aug-19-13Initiated Stifel Buy $16
Apr-21-17 02:00AM  Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation GlobeNewswire
Apr-17-17 08:40AM  Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? Zacks
Apr-03-17 09:30AM  Conatus Pharmaceuticals and MannKind Look Forward to Promoting Their Brand Accesswire
Mar-30-17 08:46AM  Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst' Benzinga +17.93%
Mar-27-17 07:30AM  Conatus to Present at Upcoming Investor Conferences GlobeNewswire
Mar-23-17 01:04PM  CONATUS PHARMACEUTICALS INC. Financials
Mar-21-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and -6.55%
Mar-16-17 04:09PM  CONATUS PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report -6.52%
11:11AM  Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4 Zacks
Mar-15-17 04:46PM  Conatus reports 4Q loss Associated Press +6.05%
04:07PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates GlobeNewswire
07:07AM  Q4 2016 Conatus Pharmaceuticals Inc Earnings Release - After Market Close
Mar-08-17 04:05PM  Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 07:24AM  Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store? Zacks
Feb-17-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
Feb-07-17 07:33AM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
07:30AM  Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member GlobeNewswire
Feb-06-17 07:30AM  Conatus to Present at BIO CEO & Investor Conference GlobeNewswire +17.01%
Feb-02-17 04:05PM  Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management GlobeNewswire
Feb-01-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-26-17 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement -5.18%
Jan-13-17 06:45AM  Short Interest In Conatus Pharmaceuticals Surges
Jan-12-17 08:38AM  Henry Schein Hurt by Higher Costs, Lacks Growth Drivers
07:07AM  Walgreens Teams Up with Fedex to Boost Retail Performance
06:46AM  NuVasive at 52-Week High on Preliminary Results, MHLW Nod
Jan-11-17 10:31AM  Can The Uptrend Continue for Conatus (CNAT)?
07:13AM  Align Poised On Global Expansion & Invisalign Teen Growth
Dec-30-16 11:47AM  Traders Are Cleaning Out Their Portfolios
Dec-29-16 01:10PM  Conatus Pharmaceuticals Significant Joint-Venture Review and Analysis of Third Quarter 2016 Results Accesswire
Dec-28-16 09:00AM  Are Options Traders Betting on a Big Move in Conatus Pharmaceuticals (CNAT) Stock? -13.58%
Dec-23-16 11:39AM  Conatus Pharmaceuticals, Inc. :CNAT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016 +17.51%
08:40AM  Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock
Dec-21-16 10:10AM  Company News for December 21, 2016 -8.67%
09:25AM  Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
09:15AM  Today's Reports on Biotech Movers ACADIA Pharmaceuticals and Conatus Pharmaceuticals Accesswire
Dec-20-16 12:00PM  Banking Sector Leading Rally in U.S. Markets +141.33%
10:46AM  General Mills falls on miss, BlackBerry's profit surprise, Facebook faces EU probe over WhatsApp merger
10:37AM  Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT) at Insider Monkey
10:30AM  Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal
08:53AM  Conatus Stock Up on Liver Drug Collaboration with Novartis
08:50AM  Conatus More Than Doubles on Key License Collaboration Agreement
08:15AM  Dow closes in on 20K, Apple talks to India and Uber losses mount
05:54AM  Dow futures point to slow march higher toward key 20,000 mark at MarketWatch
Dec-19-16 10:02PM  Futures Point North; Asia Mixed, Despite European Attacks
05:21PM  Conatus shares skyrocket after Novartis license deal at MarketWatch
04:31PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or P
04:30PM  Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan GlobeNewswire
Nov-14-16 08:00AM  Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting GlobeNewswire
Nov-09-16 08:09AM  Conatus (CNAT) Reports Narrower-than-Expected Loss in Q3 +7.05%
07:30AM  Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference GlobeNewswire
Nov-08-16 04:28PM  Conatus reports 3Q loss
04:07PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates GlobeNewswire
07:07AM  Q3 2016 Conatus Pharmaceuticals Inc Earnings Release - After Market Close
Nov-03-16 07:30AM  Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis GlobeNewswire -5.06%
Nov-01-16 04:05PM  Conatus Pharmaceuticals to Report Third Quarter 2016 Financial Results GlobeNewswire -10.73%
Oct-31-16 09:11AM  Conatus (CNAT) Q3 Earnings: What's in Store for the Stock?
Oct-04-16 10:34AM  Why Facebook, Netflix, and Three Other Stocks Are in Spotlight Today at Insider Monkey +6.12%
Oct-03-16 06:13PM  After-hours buzz: QCOM, CNAT & more at CNBC
04:12PM  Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting GlobeNewswire
Sep-22-16 03:06PM  Why Collegium Pharmaceuticals Inc (COLL), Galmed Pharmaceuticals Ltd (GLMD) and Three Other Stocks Are Registering Significant Gains Today at Insider Monkey
09:08AM  5 Biotech Stocks to Watch as Interest in NASH Increases
Sep-21-16 12:50AM  [$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal at The Wall Street Journal
Sep-20-16 09:40PM  [$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal at The Wall Street Journal +19.43%
01:02PM  NASH Hype Has These 2 Stocks Soaring, Plus the Latest On MGT Capital, PTC Therapeutics, and Cloud Peak Energy at Insider Monkey
11:46AM  Here's Why Conatus Pharmaceuticals (CNAT) Stock Is Soaring Today
Aug-30-16 11:35AM  Why The Zika News Might Not Be So Great For Conatus Pharmaceuticals Inc (CNAT) at Insider Monkey -6.00%
10:00AM  Spotlight (STLT) to Help Fund Breakthrough Drug Research
12:06AM  [$$] Potential Zika Virus Therapies Identified by Researchers at The Wall Street Journal
Aug-29-16 01:47PM  Conatus Pharmaceuticals (CNAT) Stock Surges, Liver Drug Could Treat Zika +5.26%
08:00AM  Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH PR Newswire
Aug-05-16 04:08PM  CONATUS PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
Aug-04-16 12:16PM  Conatus (CNAT) Posts Narrower Q2 Loss, Emricasan in Focus -8.86%
Aug-03-16 06:45PM  Conatus reports 2Q loss
04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates GlobeNewswire
07:07AM  Q2 2016 Conatus Pharmaceuticals Inc Earnings Release - After Market Close
Aug-02-16 10:30AM  Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
08:35AM  Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Aug-01-16 06:36PM  Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Jul-27-16 07:30AM  Conatus Pharmaceuticals to Report Second Quarter 2016 Financial Results GlobeNewswire
Jun-24-16 04:06PM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Jun-14-16 07:30AM  Conatus to Present at JMP Securities Life Sciences Conference GlobeNewswire
May-06-16 10:32AM  Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan -8.24%
May-05-16 09:30AM  Conatus' (CNAT) Q1 Loss in Line with Expectation -6.25%
07:40AM  Conatus reports 1Q loss
07:07AM  Q1 2016 Conatus Pharmaceuticals Inc Earnings Release - Before Market Open
07:01AM  CONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financi
07:00AM  Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates GlobeNewswire
May-04-16 04:05PM  Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial GlobeNewswire
11:25AM  Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More Zacks
May-03-16 06:57PM  Conatus (CNAT): Can the Stock Surprise in Q1 Earnings? Zacks
Apr-28-16 07:30AM  Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results GlobeNewswire
Apr-18-16 07:30AM  Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data GlobeNewswire
Apr-15-16 07:30AM  Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment GlobeNewswire
Apr-06-16 01:47PM  Edited Transcript of CNAT earnings conference call or presentation 9-Mar-16 9:30pm GMT +10.92%
12:25PM  Penny Stocks: Wednesday's List Of Trending Micro Cap And Small Cap Equities Accesswire
Apr-05-16 07:30AM  Conatus to Present at Needham Healthcare Conference GlobeNewswire
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cashion CharlesSVP, Finance, CFO and Sec.Jan 09Option Exercise0.9942,42442,00042,424Jan 11 04:01 PM
Mento Steven JPresident, CEO & DirectorDec 20Option Exercise1.2141,41450,09141,414Dec 22 04:04 PM
Van Wart HaroldDirectorOct 27Option Exercise0.2518,1814,54518,181Oct 31 04:37 PM